A single arm, multicenter, open-label, 52-week, the omnibus extension study to evaluate the safety and efficacy of telbivudine in the fifth year of treatment in chinese patients with compensated chronic hepatitis B and are HBV [hepatitis B virus] DNA PCR [polymerase chain reaction] negative at the end of year 4 treatment.
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 13 Apr 2009 Planned end date changed from 1 Sep 2009 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 18 Apr 2008 New trial record.